Concomitant utilization of XANAX with solid CYP3A inhibitors provides a profound impact on the clearance of alprazolam, resulting in elevated concentrations of alprazolam and enhanced chance of adverse reactions [see Clinical Pharmacology (12.three)]. Avoidance or managementNever acquire opioid agony medicines with benzodiazepines or other medicine